Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis.
Mark C GenoveseJoel M KremerRonald F van VollenhovenRieke AltenJuan Jose ScaliAriella KelmanSophie DimonacoLaura BrockwellPublished in: Arthritis & rheumatology (Hoboken, N.J.) (2017)
Transaminase elevations with tocilizumab were frequent, but rates of hepatic SAEs were low in this clinical trial data set. Regular monitoring, with dose adjustment of tocilizumab/DMARDs for persistent elevations, is recommended.
Keyphrases
- rheumatoid arthritis
- clinical trial
- rheumatoid arthritis patients
- disease activity
- juvenile idiopathic arthritis
- electronic health record
- big data
- ankylosing spondylitis
- phase ii
- phase iii
- interstitial lung disease
- study protocol
- open label
- double blind
- systemic lupus erythematosus
- randomized controlled trial
- data analysis
- machine learning
- combination therapy
- systemic sclerosis